clinical trial · NCT06941870
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Factor VIII DeficiencyEfanesoctocog alfa
brief summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
started
Sep 23, 2025
primary completion
Oct 25, 2027
completion
Oct 25, 2027
last updated
Nov 18, 2025
official title
Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol